Treatment with the approved therapy Esbriet (pirfenidone), marketed by Genentech, helps preserve lung function in people with idiopathic pulmonary fibrosis (IPF), real-world data from the PROOF registry show. The results were reported in “Longitudinal clinical outcomes in a real-world population of patients with idiopathic…
News
Investigational therapy AD-214 raised no safety concerns in preliminary studies in non-human primates, and AdAlta, the therapy’s developer, is now planning to launch a Phase 1 clinical trial in humans, the company announced. AD-214 is a modification of AdAlta’s original lead candidate for the treatment of pulmonary fibrosis…
Activating a dopamine receptor on fibroblast cells (connective tissue cells) may help slow, or even reverse, fibrosis in mice, a study suggests. The study, “Selective YAP/TAZ inhibition in fibroblasts via dopamine receptor D1 agonism reverses fibrosis,” was published in the journal Science Translational Medicine. Fibrosis — abnormal…
MUC5B genetic variants and shorter telomeres — or chromosome endings — are risk factors associated with greater lung damage and poorer survival in Chinese patients with idiopathic pulmonary fibrosis (IPF), a study has revealed. The study, “The relationship between MUC5B promoter, TERT polymorphisms and telomere…
A genetic variant at the IFNL3 gene is linked to raised levels of IFN-lambda 3 in the blood and is associated with the presence of pulmonary fibrosis in patients with systemic sclerosis, but it does not represent a risk factor for worsening of skin fibrosis in these patients, a…
People with non-small cell lung cancer (NSCLC) who also have pulmonary fibrosis and emphysema are at a greater risk of acute flares following cancer treatment that includes chemotherapy, surgery, or radiotherapy, a study from South Korea reports. The study “Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in…
Indalo Therapeutics announced that dosing has begun in the first patient enrolled in its Phase 1 trial assessing the safety, tolerability, and properties of IDL-2965, the company’s lead candidate to treat fibrotic diseases including idiopathic pulmonary fibrosis (IPF). IDL-2965 is an oral, selective antagonist of three types…
Veracyte announced new data further supporting its Envisia Genomic Classifier as a useful tool in helping doctors to diagnosis idiopathic pulmonary fibrosis (IPF) with greater confidence and without the need for surgery to biopsy lung…
Healthy and idiopathic pulmonary fibrosis (IPF) lung cells respond differently to transforming growth factor-beta 1 (TGF-beta 1) — a key mediator of fibrosis — both in terms of gene activity and DNA methylation, likely due to the fibrotic environment that IPF cells are exposed to in the lungs,…
No significant differences in survival rates, extending out 10 years, were found in idiopathic pulmonary fibrosis (IPF) patients given either a single- or double-lung transplant, a study reports. These findings, based on data cover more than 2,000 IPF patients who underwent either, suggest a bias in studies favoring a…
